Skip to main content
. 2023 Nov 21;15(6):2697–2709. doi: 10.14336/AD.2023.1115-1

Table 1.

Baseline characteristics of intrinsic capacity decline subtypes.

Mean ± SD, or number (%) Total Robust with mild decline Hearing loss with cognitive decline PCD with depression Severe IC decline P value
Number 1,782 902 197 373 310
Sex (Female) 865 (48.5) 337 (37.4) 62 (31.5) 219 (58.7) 247 (79.7) <0.01
Age (Year)
65-69 106 (6.0) 67 (7.4) 7 (3.6) 24 (6.4) 8 (2.6) <0.01
70-74 460 (25.8) 278 (30.8) 35 (17.8) 114 (30.6) 33 (10.7)
75-79 505 (28.3) 266 (29.5) 54 (27.4) 107 (28.7) 78 (25.2)
80-84 475 (26.7) 213 (23.6) 60 (30.5) 85 (22.8) 117 (37.7)
85+ 236 (13.2) 78 (8.7) 41 (20.8) 43 (11.5) 74 (23.9)
The level of education
No schooling 654 (36.7) 216 (24.0) 67 (34.0) 133 (35.7) 238 (76.8) <0.01
Elementary 695 (39.0) 384 (42.6) 84 (42.6) 168 (45.0) 59 (19.0)
Junior/Senior High 319 (17.9) 225 (24.9) 30 (15.2) 53 (14.2) 11 (3.6)
College/Graduate school 114 (6.4) 77 (8.5) 16 (8.1) 19 (5.1) 2 (0.7)
Smoking 261 (14.7) 162 (18.0) 30 (15.2) 47 (12.6) 22 (7.1) <0.01
Alcohol use 395 (22.2) 260 (28.8) 42 (21.3) 72 (19.3) 21 (6.8) <0.01
Visual acuity
Very clear 222 (12.5) 162 (18.0) 15 (7.6) 35 (9.4) 10 (3.2) <0.01
Clear 797 (44.7) 485 (53.8) 89 (45.2) 156 (41.8) 67 (21.6)
Average 372 (20.9) 186 (20.6) 46 (23.4) 80 (21.5) 60 (19.4)
Poor 351 (19.7) 67 (7.4) 45 (22.8) 94 (25.2) 145(46.8)
Very poor 40 (2.2) 2 (0.2) 2 (1.0) 8 (2.1) 28 (9.0)
Hearing ability
Very clear 410 (23.0) 288 (31.9) 9 (4.6) 84 (22.5) 29 (9.3) <0.01
Clear 790 (44.3) 441 (48.9) 18 (9.1) 206 (55.2) 125 (40.3)
Average 314 (17.6) 144 (16.0) 22 (11.2) 83 (22.3) 65 (21.0)
Poor 260 (14.6) 29 (3.2) 144 (73.1) 0 (0) 87 (28.1)
Very poor 8 (0.5) 0 (0) 4 (2.0) 0 (0) 4 (1.3)
ADL (0-6) 5.5 ± 1.3 6.0 ± 0.4 5.4 ± 1.5 5.2 ± 1.7 4.8 ± 2.0 <0.01
IADL (0-6) 4.5 ± 1.8 5.4 ± 1.1 4.2 ± 1.9 4.0 ± 1.8 2.7 ± 1.9 <0.01
Mobility performance (0-9) 5.7 ± 2.7 7.2 ±2.0 5.2 ± 2.6 4.2 ± 2.5 3.4 ± 2.3 <0.01
SPMSQ (0-9) 7.4 ± 1.9 8.1 ± 1.4 7.7 ± 1.5 7.4 ± 1.7 5.2 ± 2.1 <0.01
CES-D (0-30) 5.6 ± 6.1 2.6 ± 3.3 6.8 ± 6.0 10.8 ± 6.9 8.3 ± 6.9 <0.01
Quality of life (0-12) 8.1 ± 2.9 9.2 ± 2.3 8.1± 2.9 6.7 ± 3.2 7.0 ± 3.1 <0.01
Comorbidities
Hypertension 867 (48.7) 401 (44.5) 112 (56.9) 191 (51.2) 163 (52.6) <0.01
Diabetes mellitus 314 (17.6) 126 (14.0) 48 (24.4) 83 (22.3) 57 (18.4) <0.01
Hyperlipidemia 276 (15.5) 134 (14.9) 38 (19.3) 64 (17.2) 40 (12.9) 0.19
Heart disease 480 (26.9) 196 (21.7) 62 (31.5) 133 (35.7) 89 (28.7) <0.01
Stroke 115 (6.5) 36 (4.0) 21 (10.7) 28 (7.5) 30 (9.7) <0.01
Cancer 76 (4.3) 35 (3.9) 12 (6.1) 23 (6.2) 6 (1.9) 0.02
COPD or asthma 232 (13.0) 81 (9.0) 39 (19.8) 73 (19.6) 39 (12.6) <0.01
Arthritis 417 (23.4) 143 (15.9) 42 (21.3) 128 (34.3) 104 (33.6) <0.01
Gastric ulcer 394 (22.1) 175 (19.4) 48 (24.4) 105 (28.2) 66 (21.3) <0.01
Hepatobiliary disease 169 (9.5) 75 (8.3) 29 (14.7) 93 (10.5) 26 (8.4) 0.04
Cataract 893 (50.1) 417 (46.2) 108 (54.9) 185 (49.6) 183 (59.0) <0.01
Chronic kidney disease 189 (10.6) 71 (7.9) 29 (14.7) 51 (13.7) 38 (12.3) <0.01
Gout 186 (10.4) 88 (9.8) 19 (9.6) 48 (12.9) 31 (10.0) 0.39
Osteoporosis 276 (15.5) 134 (14.9) 38 (19.3) 64 (17.2) 40 (12.9) 0.18
Multimorbidity
0 214 (12.0) 149 (16.5) 17 (8.6) 24 (6.4) 24 (7.7) <0.01
1 319 (17.9) 197 (21.8) 23 (11.7) 49 (13.1) 50 (16.1)
2 418 (23.5) 216 (24.0) 43 (21.8) 85 (22.8) 74 (23.9)
3 831 (46.6) 340 (37.7) 114 (57.9) 215 (57.6) 162 (52.3)

SD, standard deviation; PCD, physio-cognitive decline; SPMSQ, Short Portable Mental State Questionnaire; CES-D, Center for Epidemiologic Studies Depression; ADL, activities of daily living; IADL, instrumental activities of daily living; COPE, chronic obstructive pulmonary disease